Other trials of great interest explore the safety and efficacy of ipilimumab in combination with other immune modulators, and targeted therapies including anti-VEGF and EGFR monoclonal antibodies, and BRAF inhibitors in melanoma and other solid tumors; combinations with chemotherapy in lung, prostate, melanoma, pancreas, and other tumor types. Here, VEGFA is linked to neoplasm.